{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:56:13Z","timestamp":1789750573794,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We constructed a web-based database of 3748 anonymized patients diagnosed with pancreatic ductal adenocarcinoma. MPC patients who received first-line FFX or GNP were enrolled. Overall survival (OS), progression-free survival, grade III to IV toxicity, and cross-over treatment were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 413 patients (232 vs. 181, FFX vs. GNP; all data are presented in this sequence) were eligible. Median age was 63 years (60 vs. 69\u2009y) with 43% (39% vs. 47%) comprising female individuals. The major metastatic sites were the liver (64%), peritoneum (25%), and distant lymph nodes (18%). The median OS was 11.5 versus 12.7 months (hazard ratio [HR]=0.87, 95% confidence interval [CI]: 0.68-1.12, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.286), and median progression-free survival was 7.5 versus 8.1 months (HR=0.92, 95% CI: 0.70-1.20, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.517), respectively. The frequency of grade III to IV febrile neutropenia was higher in the FFX group (18% vs. 11%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.040), and that of peripheral neuropathy was higher in the GNP group (8% vs. 14%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.046). The chance to receive second-line chemotherapy was higher in the GNP group (45% vs. 56%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.036). In the cross-over treatment, the median OS of the FFX-GNP group (n=43) and the GNP-FFX group (n=47) was 16.8 versus 17.7 months (HR=0.79, 95% CI: 0.44-1.41, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.425).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>FFX and GNP showed similar efficacy and comparable toxicity in MPC patients. Although the GNP group had a higher chance to receive second-line chemotherapy, they did not have improved overall survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000730","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T12:04:38Z","timestamp":1593518678000},"page":"654-659","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer"],"prefix":"10.1097","volume":"43","author":[{"given":"Jong-chan","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Myung","family":"Woo","sequence":"additional","affiliation":[{"name":"Center for Liver Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Woo","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Yeol","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Liver Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Soung","family":"Cha","sequence":"additional","affiliation":[{"name":"Cancer Big Data Center, National Cancer Center, Goyang, Gyeonggi Province, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philiip","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Big Data Center, National Cancer Center, Goyang, Gyeonggi Province, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaihwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyeok","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE\u20145: a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s12325-018-0784-z","article-title":"Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States","volume":"35","author":"Kim","year":"2018","journal-title":"Adv Ther"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-018-3611-y","article-title":"Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer","volume":"82","author":"Tahara","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10637-018-0598-5","article-title":"Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis","volume":"36","author":"Kang","year":"2018","journal-title":"Invest New Drugs"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"566","DOI":"10.21037\/jgo.2017.02.02","article-title":"Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine plus nab-paclitaxel in unresectable pancreatic cancer","volume":"8","author":"Muranaka","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/1078-0432.CCR-17-2180","article-title":"Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and cytokeratin-81 correlates with outcome and treatment response","volume":"24","author":"Muckenhuber","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1245\/s10434-018-6512-8","article-title":"FOLFIRINOX versus gemcitabine\/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma","volume":"25","author":"Dhir","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"e0218642","DOI":"10.1371\/journal.pone.0218642","article-title":"A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy","volume":"14","author":"Kaissis","year":"2019","journal-title":"PLoS One"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","article-title":"Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity","volume":"76","author":"Lee","year":"2017","journal-title":"Eur J Cancer"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12029-017-0028-5","article-title":"A real-world comparison of FOLFIRINOX, gemcitabine plus nab-paclitaxel, and gemcitabine in advanced pancreatic cancers","volume":"50","author":"Wang","year":"2019","journal-title":"J Gastrointest Cancer"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:07:09Z","timestamp":1693714029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000730"}},"subtitle":["Using Korean Pancreatic Cancer (K-PaC) Registry"],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000730","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}